Detailed Information
Cited 0 time in 
Cited 7 time in 
Cited 7 time in
Metadata Downloads
Antiviral Efficacy of Pralatrexate against SARS-CoV-2
- Authors
- Bae, Joon-Yong; Lee, Gee Eun; Park, Heedo; Cho, Juyoung; Kim, Jeonghun; Lee, Jungmin; Kim, Kisoon; Il Kim, Jin; Park, Man-Seong
- Issue Date
- May-2021
- Publisher
- KOREAN SOC APPLIED PHARMACOLOGY
- Keywords
- Antiviral; COVID-19; Drug repurposing; SARS-CoV-2
- Citation
- BIOMOLECULES & THERAPEUTICS, v.29, no.2, pp 268 - 272
- Pages
- 5
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- BIOMOLECULES & THERAPEUTICS
- Volume
- 29
- Number
- 2
- Start Page
- 268
- End Page
- 272
- ISSN
- 1976-9148
2005-4483
- Abstract
- Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.
- Files in This Item
- There are no files associated with this item.
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Bae, Joon Yong
- Research Institute (Institute for Viral Diseases)